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Purpose: To compare dialysis access patency rates and identify risk factors for failure. 
Methods: All access procedures at our institution from 1987 to 1996 were reviewed. 
Primary procedures were surgically implanted dual-lumen c tral venous hemodialysis 
catheters (SIHCs), peritoneal dialysis catheters (PDCs), arteriovenous fi tulas (AVFs), 
and prosthetic shunts (PTFEs). 
Results: Five hundred eighty-five primary procedures (236 PTFEs, 87 AVFs, 112 SIHCs, 
and 150 PDCs) and 259 secondary procedures (215 PTFEs, 14 AVFs, 0 SIHCs, and 30 
PDCs) were performed on 350 patients. By life table analysis, SIHCs exhibited the lowest 
primary patency rate (9% at 1 year; p < 0.0001), whereas PDCs had the highest primary 
patency rate (57% at 1 year; p < 0.02). The primary patency rates of AVFs and PTFEs was 
similar, with 43% and 41% 1-year patency rates, respectively (p = 0.70). Less-stringent 
reporting methods would have increased apparent 1-year patency rates by 9% to 41%. 
With regard to secondary patency, there was no significant difference between PTFEs and 
PDCs, with 1-year patency rates of 59% and 70%, respectively (p= 0.62), but PTFEs were 
more frequently revised. In addition, there was no significant difference between AVF 
and PTFE secondary patency rates, with 1-year patency rates of 46% and 59%, respec- 
tively. Early differences in patency rates for AVFs, PTFEs, and PDCs diminished over 
time, and at 4 years AVFs had the best secondary patency rate (p = 0.6). The most 
common reasons for access failure were: PTFEs, thrombosis; AVFs, thrombosis and 
failure to mature; SIHCs, inadequate dialysis; PDCs, infection and inadequate exchange. 
By regression analysis, a history of a previous unsalvageable PTFE was the only signifi- 
cant risk factor for failure of a subsequent PTFE (p < 0.01), and the risk of graft failure 
increased exponentially with the number of previous PTFE shunts. Diabetes was the only 
significant risk factor for failure of PDCs (p < 0.02; odds ratio, 2.0). 
Conclusions: The patency rate for PTFEs is similar to that for AVFs, but AVFs require 
fewer revisions. When replacing a failed access graft, the risk of PTFE failure increases 
with the number of prior unsalvageable PTFE shunts. PDCs have excellent patency rates, 
but failure rates are doubled in patients with diabetes. Because of poor patency rates and 
inadequate dialysis flow rates, SIHCs should be avoided when possible. Reporting 
methods dramatically affect apparent patency rates, and reporting standards are needed 
to allow meaningful comparisons in the dialysis access literature. (J Vasc Surg 1997; 
26:1009-19.) 
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Decisions involving dialysis access have become 
important issues in American health care. There are 
currently more than 120,000 patients who undergo 
chronic dialysis in the United States, 1 and access 
complications have emerged as the leading cause of 
hospitalization for this patient population. 2 The av- 
erage patient charge for attempted salvage of a failed 
hemodialysis access graft in 1994 was $4350, s and 
the estimated Medicare expenditure for dialysis ac- 
cess complications in 1993 was $150 million. 2 Dial- 
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ysis patients are hospitalized more than 3 days out of 
every 3 month period, and their perceived overall ife 
satisfaction is significantly ower than normal control 
patients or transplant recipients. 4 Thus establishing 
adequate access while minimizing complications i  a 
primary goal of dialysis research initiatives,  The cen- 
tral management questions revolve around which 
method is best for initial dialysis access and which 
treatment s rategies are appropriate after primary ac- 
cess failure. 
With regard to initial dialysis access, current op- 
tions include surgically implanted ual-lumen central 
venous hemodialysis catheters (SIHCs), peritoneal 
dialysis catheters (PDCs), arteriovenous fistulas 
(AVFs), and prosthetic bridge graft shunts (of which 
the predominant ype is polytetrafluoroethylene 
[PTFE]). Information regarding these options is 
sometimes conflicting. For instance, some investiga- 
tors have found the durability of SIHC access to be 
relatively poor ,  6 whereas others have found SIHC 
durability equivalent to other forms ofhemoaccess. 7 
Even for the most common forms of access, namely 
AVFs and PTFEs, comparison studies ofpatency are 
contradictory, indicating AVFs may be inferior, 
equivalent, or superior to PTFEs. 8-1° Moreover, 
there are few studies that compared the longevity of 
hemodialysis access with that of peritoneal dialy- 
sis. ll,12 As a result of these conflicts, objective mea- 
sures such as patency rate or adequacy of dialysis have 
less influence on the choice of access than physician 
preference and geographic bias. 13-17 
Although the decisions regarding initial dialysis 
access are complex, decisions after one or more ac- 
cess failures are especially problematic. If a prosthetic 
graft fails repeatedly, when should this access be 
abandoned? What are the risk factors for recurrent 
thrombosis? Hill and Donato ~8 noted that only 6.8% 
of patients accounted for more than 48% of the 
secondary procedures required to maintain hemoac- 
cess patency, but there were no unique determinants 
of that group. With SIHCs and PDCs, catheter revi- 
sion is only occasionally an option, but information 
supporting replacement of a catheter or changing to 
a different form of dialysis remains largely undefined. 
This study was designed to compare primary and 
secondary patency rates for the four major types of 
dialysis access and to identify risk factors for subse- 
quent access failure. 
/ v lETHODS 
We retrospectively reviewed all surgical proce- 
dures performed for chronic dialysis access at Dart- 
mouth-Hitchcock Medical Center (Lebanon, N.H.) 
between January 1987 and January 1996. This insti- 
tution is the single provider of home- or center-based 
dialysis for a patient population geographically o- 
cated in central Vermont and New Hampshire. The 
review includes only surgical procedures and specifi- 
cally excludes temporary access with percutaneous 
hemodialysis catheters. All procedures were catego- 
rized as primary access or revisions and were subcat- 
egorized as SIHC, AVF, PTFE, or PDC. As a means 
for comparison, "patency" was used to describe con- 
tinuous useful function of an access, regardless of 
type. Access "failure" was defined as any problem 
that required another surgical procedure to maintain 
dialysis access, including thrombosis; infection; pseu- 
doaneurysm; hemorrhage; stenosis with difficulty 
maintaining adequate flow rates; patient dissatisfac- 
tion causing achange to another type of access; poor 
function (inadequate dialysis); and congestive heart 
failure, distal ischemia, or edema that require liga- 
tion. Failure was defined on an intention to treat 
basis. Thus AVFs that failed to mature are included 
as failures, even if no attempt at dialysis was made. 
Filling the lumen of SIHCs with a lytic agcnt was not 
considered a revision or failure if it resulted in a 
functioning catheter with no need for revision. 
Decisions regarding access type were made by 
surgeon preference, allowing for input from the 
nephrologist and patient preferences after counsel- 
ing. Although no formal protocol was in place, the 
general practice was to determine first whether the 
patient would have hemodialysis or peritoneal dialy- 
sis. For hemodialysis patients, the preference was to 
implant AVFs in all patients who were bclieved to be 
suitable candidates, using PTFEs when veins were 
not adequate for AVFs and using SIHCs for patients 
who had unsuitable arm veins, previous problems 
with AVFs or PTFEs, or other mitigating circum- 
stances. Percutaneous hemodialysis catheters were 
used for temporary access and are excluded from this 
analysis. 
Life table analysis was used to generate primary 
and secondary patency rates in accordance with the 
SVS/ISCVS reporting standards for lower extremity 
ischemia) 9 Log-rank testing was used to compare 
patency results for different access types. Censored 
endpoints for this analysis were death, transplanta- 
tion, improvement in renal function, loss of follow- 
up, transfer of care to another institution, and access 
survival to the end of the study period. A patient was 
considered "lost to follow-up" when dialysis records 
ended, no record of transplantation r death could 
be found, and the paticnt was not known to have 
transferred care. The influence of age, gender, diabe- 
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Big. 1. Primary patency life table. Patency is defined as useful access function. One-year 
primary patency rates r  shown in parentheses. Standard error is less than 10% at all times. 
tes, smoldng history, and previous access history on 
patency was examined using multivariate propor- 
tional hazards regression analysis. All statistical anal- 
ysis was performed using commercially available soft- 
ware (StatView 4.5, Abacus Concepts Inc., Berkeley, 
Calif.) on a personal computer (Macintosh, Apple 
Computer Inc., Cupertino, Calif.). 
RESULTS 
Patient population. From January 1987 to Jan- 
uary 1996, 844 procedures were performed in 350 
patients. The average patient age at the time of the 
primary procedure was 59 years (range, 13 to 87), 
and patients older than 65 years comprised 46% of 
the population. Men comprised 61% of patients, dia- 
betes mellitus was present in 41%, and 53% were 
lifetime nonsmokers. Four patients had positive re- 
sults of tests for hyperc0agulable states, but the ma- 
jority were unknown. During the course of the study, 
102 of the 350 patients (29%) died. Only 59 of the 
' 844 procedures (7%) had loss of follow-up or transfer 
of care. 
Primary procedures. During the study period, 
585 primary procedures (236 PTFEs, 87 AVFs, 112 
SIHCs, and 150 PDCs) were performed. The mean 
duration of follow-up for these procedures was 21.5 
months. Of the prosthetic shunts, all were performed 
with PTFE: 82% were forearm loop grafts, 2% fore- 
arm straight grafts, 2% upper arm loop grafts, 11% 
upper arm straight grafts, and 3% lower extremity 
grafts. Brescia-Cimino fistulas comprised 87% of 
AVFs, and the remainder of AVFs were placed in the 
antecubital fossa or upper arm. SIHCs were all 
cuffed, dual-lumen catheters, urgically placed in the 
internal jugular vein in 65% of cases and in the sub- 
clavian vein in 28%. All of the PDCs were surgically 
implanted, cuffed Tenckhoff catheters. 
Primary patency. By life table analysis (Fig. 1), 
the primary patency rates of AVFs and PTFEs were 
similar, with 1-year patency rates of 43% and 41%, 
respectively (p < 0.7). After exclusion of fistulas that 
failed to mature, the AVF patency rate at 1-year 
improved from 43% to 54% (p < 0.09 vs PTFE). 
SIHCs exhibited the lowest primary patency rate (9% 
at 1 year; p < 0.0001 vs AVFs and PTFEs), whereas 
PDCs exhibited the highest primary patency rate 
(57% at 1 year; p < 0.02 vs AVFs and PTFEs). 
Despite arly differences, the primary patency rates of 
PDCs, AVFs, and PTFEs were similar after 2 years 
(Fig. 1). 
Secondary procedures. Secondary procedures 
included revisions of 215 PTFEs, 14 AVFs, and 30 
PDCs. No SIHCs were surgically revised. More than 
90% of PTFEs underwent a secondary procedure 
(215 of 236), and the majority of these were throm- 
bectomy with anastomotic patch angioplasty (44%). 
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Fig. 2. Secondary patcncy life table. Patency is defined as useful access function. One-year 
secondary patency rates are shown in parentheses. Standard error is less than 10% at all times. 
In 26% of PTFE thromboses, no mechanical prob- 
lem could be identified by completion angiography, 
and the procedure included thrombcctomy alone. 
The remainder of PTFE revisions included interposi- 
tion grafts (16%), jump grafts (7%), and venous out- 
flow revisions in patent but failing grafts (7%). Anas- 
tomotic hyperplasia was the indication for 70% of 
PTFE revisions. Only 16% of AVFs underwent revi- 
sion (14 of 87). Most AVF revisions (42%) were 
patch angioplasty or interposition grafts performed 
for falling but patent grafts. Most of the other AVF 
revisions (30%) were thrombectomy with patch an- 
gioplasty. A surprisingly arge number of PDCs were 
revised (30 of 150; 20%), and most of these were 
catheter repositioning using laparoscopic techniques. 
No revisions involved lyric therapy, and local admin- 
istration of a lyric agent within an SIHC was not 
considered a revision. The rate of revisions per access 
per year was 0.5 for PTFEs, 0.07 for AVFs, and 0.1 
for PDCs. 
Secondary patency. More frequent revisions 
improved PTFE patency rates relative to those of 
PDCs, and there was no significant difference in the 
secondary patency rates of PTFEs and PDCs (59% 
and 68%, respectively, at 1 year; p = 0.62; Fig. 2). 
Despite the low rate of revisions for AVFs, there was 
also no significant difference between the AVF and 
PTFE secondary patency rates (46% and 59%, respec- 
tively, at 1 year; p = 0.07). Power analysis indicated 
that more than 350 patients per group would be 
needed to  detect hese small differences in the sec- 
ondary patency rate with adequate statistical power. 
Notably, however, apparent differences in secondary 
patency rates for AVFs, PTFEs, and PDCs dimin- 
ished over time. At late time points, AVFs had the 
highest secondary patency rate (p = NS; Fig. 2). 
Excluding the AVFs that failed to mature improved 
the AVF secondary patency rate to 55% at 1 year and 
eliminated the trend toward the better patency rate 
of PTFE at early time periods (AVF 55% vs PTFE 
59%; p -- 0.73). 
For the 215 PTFE revisions, there appeared to be 
a reduced mean patency rate with each successive 
revision (revisions l, 2, and 3 extended patency by 
8.6 months, 6.8 months, and 5.2 months, respec- 
tively), but these differences did not reach statistical 
significance. The patency rate of PTFE revisions at 1 
year was poor compared with that of new primary 
PTFEs, with 1-year patency rates of 23%, 16%, and 
17% for revisions 1, 2, and 3. Note that we refer here 
to the patency of the revision itself, not the original 
primary patency plus the extended patency provided 
by the revision. For PTFE thrombosis, the type of 
revision (patch, interposition graft, etc.) had no effect 
on the patency rate. Notably, all PTFE failures 
treated with thrombectomy alone had completion 
angiography, and the patency rates were similar to 
other procedures performed for PTFE thrombosis 
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(1-year patency rate, 21%; p = 0.36). In contradis- 
tinction, revision of a PTFE stenosis before throm- 
bosis appeared to improve patency if the revision 
could be accomplished with simple patch angioplasty 
(36% 1-year patency rate, 19% for revisions after 
thrombosis; p = 0.06). Treating a failing graft was 
not beneficial if a more complicated revision were 
required (21% 1-year patency rate for revision with- 
out thrombosis vs 19% for revision with thrombosis; 
p = 0.57). AVFs were rarely revised, and revisions 
extended AVF patency by a mean of 6 months. Revi- 
sions for thrombosed AVFs were less successful, with 
a mean duration ofpatency of less than 4 months. Of 
the 30 PDCs that were revised, the mean patency 
duration was extended by 14.3 months (1-year pa- 
tency rate, 48%). 
Failure modes. The most common types of fail- 
ure for a primary access were: PTFEs, thrombosis 
(70% of failures); AVFs, thrombosis (44% of failures) 
and failure to mature (31% of failures); SIHCs, inad- 
equate dialysis flow rate (51% of failures); PDCs, 
infection (37% of failures) and inadequate exchange 
(34% of failures). No AVFs were revised because of 
infection, whereas 9% of PTFE revisions were attrib- 
utable to infection. Patients were least satisfied with 
SIHCs and PDCs (Table I). 
Risk factors for failure. By multivariate r gres- 
sion analysis, age, gender, diabetes, history of failed 
PDC, and smoldng were not significant contributors 
to hemoaccess failure. A history of prior failed PTFE 
(PTFE that was not considered salvageable) was the 
only significant risk factor for failure of a subsequent 
PTFE graft at a new site (p < 0.01). The risk of 
failure for a new PTFE increased with the number 
of previous failed primary grafts. The odds ratios 
for primary failure were 1.4, 1.9, and 2.6 for one, 
two, and three prior failed grafts. The effect on 
expected secondary patency rates was even greater, 
with odds ratios for failure of 1.6, 2.7, and 4.4 for one, 
two, and three prior failed grafts (Fig. 3). To illustrate 
these numbers in clinical context, if a patient has had 
two previous PTFEs that could not be salvaged, a third 
PTFE at a new site is twice as likely to have primary 
failure (primary patency), and the patient is nearly three 
times as likely to lose the use of that shunt despite 
revision (secondary patency; Fig. 3). It is important to 
note that these data are related to the number of prior 
prosthetic grafts. A prior failed AVF was not a risk factor 
for failure of subsequent PTFEs. In fact, PTFEs placed 
ipsilateral to a failed wrist AVF had a 1-year primary 
patency rate of 59% for the new PTFE, compared with 
a 41% 1-year primary patency rate for a PTFE without a
prior ipsilateral AVF. 
Table I. Causes of access failure by type 
Cause offailure A VF PTFE SIHC PDC 
Thrombosis 44% 70% 12% N/A  
Infection 0% 9% 3% 37% 
Patient dissatisfaction 7% 2% 16% 12% 
Congestive heart failure 0% 0% 0% 0% 
Poor fimction 4% 0% 51% 34% 
Bleeding 2% 3% 1% 1% 
Malposition N/A N/A 6% 3% 
Failure to mature 31% N/A  N/A  N/A  
Pseudoaneurysm formation 0% 1% N/A  N/A  
Stenosis detected while patent 7% 7% N/A N/A  
Distal extremity ischemia or swelling 4% 3% N/A N/A 
Unknown 1% 1% 8% 12% 
Primary causes of failure are shown in bold type. Data recorded as 
a percentage of total failures for each form of access (not as a 
percentage oftotal cases). 
For peritoneal dialysis catheters, multivariate re- 
gression analysis indicated that age, gender, smok- 
ing, and history of a failed PTFE were not significant 
contributors to failure. The only significant risk fac- 
tor for failure of peritoneal dialysis catheters was 
diabetes mellitus (p < 0.02; odds ratio, 2.0; for 
patients with diabetes compared with those with- 
out). Notably, this higher rate of PDC failure in 
patients who had diabetes appeared to be a result of 
inadequate xchange. Although more PDCs failed 
because of infection in patients with diabetes than in 
those without (22% vs 17% of cases), this difference 
was not statistically significant. Failure of PDCs be- 
cause of inadequate exchange was significantly more 
common in patients who had diabetes than in those 
without, however (26% vs 12% of cases; p < 0.05). 
The presence of diabetes had little affect on compar- 
isons of early patency, but became more apparent at 
later times. In our patients with diabetes, the 1-year 
primary patency rate for PDCs remains higher than 
for PTFEs (50% vs 32%), but the 2-year primary 
patency rate is slightly lower (18% for PDCs vs 20% 
for PTFEs). 
Reporting methods. To demonstrate the role 
of reporting standards, we calculated primary pa- 
tency rates for AVFs and PTFEs using several com- 
monly used methods in the dialysis access literature. 
Using the data from our study, the patency of AVFs 
can be reported as higher than PTFEs (p = NS), 
lower than PTFEs (p = NS), or twice as high as 
PTFEs (p < 0.003), as shown in Table II. Thus we 
could have chosen to report a mean primary patency 
duration for AVFs ranging from 9.7 months to 2.4 
years. To demonstrate he linkage of failure defini- 
tions with statistical methods, the apparent 1-year 
primary patency rate for AVFs calculated by life table 
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Fig. 3. Prosthetic shunt failure risk according to the number of previous hunt failures. Odds 
ratio indicates the relative risk of failure compared with a prosthetic shunt placed in a patient 
with no previous shunts. 
Table II. Differences in reporting methods 
A VF PTFE 
(mo.) (too.) p 
Arithmetic mean 9.7 8.8 0.58 
Arithmetic mean excluding 11.3 8.8 0.18 
failure to mature 
Life table mean 13.9 17.5 0.70 
Life table 50% patency 5.4 7.2 0.70 
Access registry 28.4 14.5 0.003 
Apparent patency rates and statistical significance levels depend 
heavily on the chosen reporting method. Arithmetic means are 
calculated as a simple average without regard to censoring data. 
They are usually compared with Student's t test and are strongly 
influenced by extremely early or late failures. Life table analysis 
avoids such statistical artifacts, but mean values are influenced by 
the length of follow-up. Access registry reporting usually includes 
only patients who have been successfully dialyzed for 1 month and 
excludes early failures of all types. 
analysis improves from 43% to 55% with exclusion of  
fistulas that fail to mature, and to 82% with exclusion 
of fistulas that fail to support 30 days of  dialysis 
(registry method). 
D ISCUSSION 
Data regarding relative patency rates and the 
number of surgical procedures required peryear to 
achieve adequate dialysis are important o patients, 
physicians, and third-party payors. Nonetheless, very 
few studies have directly compared patency rates for 
the four major forms of hemodialysis access at a 
single center. This population-based study provides 
data that may challenge some widely-held impres- 
sions and provide unique insights regarding primary 
access durability, secondary access trategies, and risk 
factors for dialysis access failure. 
Pr imary access. Perhaps the most controversial 
result in this study is related to the patency of native 
AVFs and PTFEs. Despite widely-held beliefs that 
AVFs are a far superior form of dialysis access, we 
found no significant difference in primary patency 
rates between AVFs and PTFEs. To make matters 
more confusing, the literature suggests that AVF 
patency may be inferior, equivalent, or superior to 
that of PTFE. sq°,15,2° On close inspection, however, 
it appears that the apparent contradictions regarding 
the relative patency of AVFs versus PTFEs can be 
explained by a combination of several factors. First, 
our study is based on strict definitions of  failure, 
including analysis on an intention-to-treat basis. 
From our perspective, if an additional procedure was 
required to maintain dialysis, the access failed. This 
strict definition includes AVFs that failed to mature, 
patent access with inadequate function, patent access 
in patients who switched to another form of dialysis 
because of dissatisfaction, patent access that required 
revision because the access was failing, and ligation of 
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AVFs or PTFEs because of distal ischemia. Most 
reports do not consider these conditions as failures, 
purposely exclude them from analysis, or do not 
mention whether they were even considered. By sim- 
ply changing these definitions of failure, we could 
have eliminated over 53% of AVF failures and 12% of 
PTFE failures. Clearly, this would have had a major 
impact on the comparison. None of the studies we 
reviewed clearly stated how they recorded every po- 
tential failure mode presented in Table I, and this 
maizes accurate comparisons of patency rates impos- 
sible. When recorded, the failure-to-mature ate 
alone may vary from 9% to 56%. 21 24 Of the studies 
we reviewed, only Palder et al. 8 performed a life table 
comparison that was based on intention to treat and 
that clearly included "failure to mature" as a failure. 
Using this more strict definition, they found that the 
AVF secondary patency rate was statistically inferior 
to that of PTFE, achieving an equivalent patency rate 
only when the AVFs that failed to mature were ex- 
cluded. Using similar definitions, we obtained similar 
results, although in our study the apparent differ- 
cnces in the secondary patency rate diminished over 
t ime.  
The second major problem when comparing di- 
alysis access results is the lack of a statistical standard. 
The access literature includes reports of mean pa- 
tency rates calculated by simple averages and com- 
pared by t tests, life table comparison reporting mean 
patency rates, life table comparison with patency 
rates at specified intervals, and various methods using 
dialysis registry and Medicare data. 2,3,9,1°,2°,25 The 
problem with mean patency data is that procedures 
with extremely short or long patency can have a 
disproportionate effect, and the length of follow-up 
can affect mean patency results by including a few 
procedures that have extraordinarily ong patency. 
These problems even affect reports of mean patency 
using life table analysis. To add to the confusion, 
dialysis access registries typically include only those 
procedures that successfully support dialysis for at 
least 30 days. The registry method eliminates prob- 
lems with patients who are not intended for chronic 
dialysis, but it eliminates early failures of all types. 
Medicare data has problems with the identification of 
procedure failures because of coding difficulties, the 
lack of codes for access location (right versus left, arm 
versus forearm), problems identifying specific causes 
of failure, and the exclusion of patients or procedures 
affected by supplemental private insurance or patient 
relocation. Adding to the confusion of multiple sta- 
tistical reporting methods, many dialysis access re- 
ports also fail to differentiate primary and secondary 
patency, resulting in reports of 70% 1-year graft pa- 
tency when the thrombosis rate alone is more than 
70% at 1 year. To demonstrate he role of reporting 
standards in the controversy surrounding the relative 
patency of AVFs and PTFEs, we could have reported 
the patency of AVFs as higher than PTFEs (p = NS), 
lower than PTFEs (p = NS), or twice as high as 
PTFEs (p < 0.003), with the mean primary patency 
duration for AVFs varying from 9.7 months to 2.4 
years. Reporting secondary patency data as "paten- 
cy" would make the results appear to vary further. 
Thus both the relative and absolute patency rates can 
appear to change dramatically despite identical data. 
We propose that future dialysis access tudies adopt 
life table analysis as a standard, reporting both pri- 
mary and secondary patency rates at specific time 
intervals, following the model of infrainguinal arte- 
rial bypass grafts. 19 Analyses hould be performed on 
an intention-to-treat basis, and definitions for pa- 
tency and failure must be reported until standard 
definitions are developed. Until this occurs, it will be 
impossible to compare results in the literature appro- 
priately. 
Given the difficulty in comparing AVF and PTFE 
patency data, what should the policy for these proce- 
dures be? The national trend is to perform fewer 
AVFs and more PTFEs, 17 perhaps as a result of frus- 
tration with early AVF failures and delayed referral 
when dialysis access is needed urgently. During this 
study, it was our general policy to offer AVFs to all 
suitable patients who chose hemodialysis. We inter- 
pret our 1-year primary AVF patency rate of 43% to 
be a reflection of this relatively liberal policy, in 
which 31% of AVFs failed to reach a size sufficient to 
support chronic dialysis access and an additional 12% 
thrombosed shortly after dialysis was attempted. 
These results are consistent with those of others, who 
report failure rates of 30% to 56% for AVFs within the 
first 3 months. 8,23,24 Despite a high early failure rate, 
the AVF patency rate is similar to that of PTFE in our 
study, especially at later time periods. We continue to 
favor AVFs over PTFEs, because patency is not the 
only criterion for access choice. In our study, AVFs 
had a lower revision rate than PTFEs (0.07 vs 0.5 
revisions/access/year) anda lower infection rate (0% 
vs 9%). These results are consistent with those of 
other studies that have noted extremely low compli- 
cation rates for AVFs that survive to functional dial- 
ysis access .  8"10'22'23'25 AVFs also preserve proximal 
veins for furore access procedures. Our results imply 
that a failed autogenous wrist fistula improves pa- 
tency for a subsequent ipsilateral prosthetic graft, 
presumably as a result of improved outflow. A1- 
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though creation of an AVF is a surgical procedure, it
can be performed with a local anesthetic on an out- 
patient basis with minimal morbidity. Thus, in suit- 
able patients, we believe AVFs are still preferable to 
PTFEs as an initial choice for hemoaccess. Better 
patient selection is clearly needed, but we could not 
find a clinical predictor of AVF failure. Others have 
also failed to identify preoperative predictors of AVF 
failure, 17,24 but intraoperative measurement of vein 
size before creation of AVFs does appear to be a 
predictor of complications. 22 Preoperative venous 
duplex may thus improve patient selection, but this 
remains to be proven. Future work must also address 
the potential for selection bias (e.g., choosing PTFE 
only for patients whose arm vein is inadequate for 
AVF), through prospective, randomized studies. 
In contrast to the difficulties in comparing AVFs 
with PTFEs, and despite similar problems with fail- 
ure definitions, the data regarding indwelling dual- 
lumen hemodialysis catheters seem clear. In the cur- 
rent study, the SIHC patency rate at 1 year was only 
9%, and no SIHC functioned longer than 18 
months. Our results are similar to those of reports of 
mean catheter survival ranging from 74 to 126 
days, 6,2°,26 although there are a minority of reports 
that suggest excellent function of SIHCs. 7,2s Again, 
definitions may be important. In our study, poor 
function was the leading cause of SIHC failure, af- 
fecting 51% of catheters. Our records indicate that 
SIHCs often do not provide adequate dialysis be- 
cause of an inability to sustain adequate flow rates. A 
more generous definition of failure might define 
these catheters as patent, because dialysis time could 
theoretically be doubled to achieve an adequate re- 
sult. However, we do not believe that maintaining 
such a poorly functioning catheter is a success for the 
patient, the dialysis unit staff, or health care costs. 
Thus SIHCs have by far the highest failure rate in 
this study. The use of two single-lumen catheters 
may improve flow rates, but we have no long-term 
follow-up for this newer procedure. Even if flow rates 
are adequate, however, long-term catheterization is 
associated with subclavian stenosis and occlusion, as 
well as decreased upper extremity hemoaccess paten- 
cy. 27 We believe that the results of the present study 
indicate that SIHCs should be used only when no 
other option is available, and this has changed the 
access trategy in our institution. 
Peritoneal dialysis is used in 14% of all patients 
who undergo dialysis in the United States, 1 but 
PDCs accounted for 26% of all primary procedures in
the current study, reflecting our relatively rural pa- 
ticnt population and perhaps institutional bias to- 
ward this form of dialysis. To our knowledge, the 
present study is the largest concurrent life table com- 
parison of PDCs and hemoaccess from a single cen- 
ter, and our analysis indicates that PDCs have a 
significantly higher primary patency rate than other 
access methods. Our primary patency rate for PDCs 
of 58% at 1 year is similar to the 42% reported in the 
literature, 28,29 and at least one other large study has 
also indicated peritoneal dialysis has patency rates 
superior to those of hemoaccess. 12 We obtained 
these results despite the fact that 43% of our PDC 
patients had diabetes. Diabetes mellitus was the only 
identifiable risk factor for PDC failure, and failure 
was twice as likely in patients with diabetes. The 
increased risk of peritonitis in patients with diabetes 
has been recognized, 3° but the incidence of PDC 
failure as a result of infection was not statistically 
higher for patients with diabetes in the present study. 
Inadequate dialysis was the most common failure 
mode in patients with diabetes and was statistically 
more likely in patients with diabetes than in those 
without. The reason for this phenomenon is un- 
known. Calculations and measurements by Gotch 
indicate that inadequate dialysis may occur more 
frequently in peritoneal dialysis than in hemodialysis, 
but he did not perform aseparate analysis for patients 
with diabetes. 14 
Should PDCs be the preferential form of dialysis 
because of superior patcncy rates? Clearly, there are 
other issues to consider. Simmons and Abress 4found 
that patients on peritoneal dialysis and hemodialysis 
had similar hospitalization rates (3.9 vs 3.3 days/ 
month; p = NS). The rate of PDC peritonitis that 
required hospitalization is approximately 0.5 epi- 
sodes per year, 29 and this appears to offset he lower 
revision rate for PDCs (0.1 revision/PDC/year vs 
0.5 revisions/PTFE/year in our study). The mortal- 
ity risk may also be higher in patients with diabetes 
who undergo peritoneal dialysis versus hemodialysis, 
but this remains controversial nd no randomized 
prospective studies exist. 13,31,32 Patient satisfaction 
must also be considered. In our study, failure as a 
result of patient dissatisfaction was intermediate for 
PDCs relative to the three forms of hemodialysis 
access. Other studies also indicate that a distinct 
subpopulation will be dissatisfied with PDCs or he- 
modialysis, but there is currently no way to prospec- 
tively identify these patients. 4,33 In general, however, 
Simmons and Abress 4 found that peritoneal dialysis 
patients cored statistically higher than hemodialysis 
patients on standard quality of life scales. Anatomic 
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issues are also important, because PDCs may not be 
acceptable as a result of previous intraabdominal in- 
fection or adhesions after laparotomy, and available 
sites for hemoaccess vary greatly in individual pa- 
tients. Finally, social issues must be taken into ac- 
count. Some patients have a strong aversion to PDCs 
or hemoaccess or prefer PDCs because of difficulty 
traveling to a dialysis center. Thus patient factors will 
often determine the choice of primary access. 
Secondary access. When a dialysis access fails, 
three options are available: revise the existing access, 
replace it with a similar type, or change the form of 
access. Although the options initially seem more dif- 
ficult than the choice of primary access, each type of 
dialysis access lends itself to a natural strategy. For 
SIHC failures, changing to a different type of access 
is the best option, because the results with primary 
SIHCs are poor, there is no effective revision strat- 
egy, and SIHC sites are limited. When PDCs fail as a 
result of poor volume exchange, we obtained excel- 
lent results with revision to a new position. Patients 
with PDCs that fail as a result of infection or inade- 
quate dialysis without obvious mechanical problems 
are encouraged to choose AVF or PTFE, especially if
the patient has diabetes. Strategies for AVF failure 
include revision, but in our experience, revisions ex- 
tended AVF life by a mean of only 6 months, and 
revisions for thrombosed AVFs were even less suc- 
cessful. Converting to PTFE after a failed AVF ap- 
pears to be a good option, but patients with failed 
AVFs who have a hypercoagulable state or dissatis- 
faction with hemodialysis are encouraged to try 
PDCs. 
The most difficult decisions for failed access occur 
with PTFE, because revision, replacement with an- 
other PTFE, and conversion to another type of ac- 
cess all have merits and problems. As patients urvive 
for longer periods on dialysis, preservation of other 
access sites becomes increasingly important and 
makes revision more appealing. In this study, the 
most common form of access revision was for pros- 
thetic grafts. Because most of these grafts failed as a 
result of anastomotic hyperplasia,  salvage attempt 
could usually be made with a small procedure and 
low patient risk. These revisions were often successful 
in extending the useful function of a PTFE shunt, 
improving the secondary patency rate at 1 year to 
59%. Others have also found that revision substan- 
tially improves graft patency. TM In this study, the 
patency rate of successive revisions appeared to di- 
minish, but we found no statistical difference for the 
first three revisions. For thrombosed grafts, the type 
of revision (e.g., patch angioplasty vs jump graft) 
also had no apparent effect on the patency rate, 
possibly because of effective use of angiography 
and selection of the appropriate revision in each 
case. For failing grafts, however, grafts amenable 
to simple patch angioplasty had better patency 
rates than grafts with more complex revisions. The 
reason for this is unclear, but studies of balloon 
angioplasty for failing grafts should not compare 
the results with those of surgical series that include 
revision of failed grafts and more complex surgical 
revisions in general. Comparing similar revision 
types, failing grafts revised with patch angioplasty 
had better patency rates than thrombosed grafts 
revised with patch angioplasty. This potentially 
beneficial effect of revision before thrombosis has 
been noted in other studies, and suggests a role for 
duplex surveillance. 3~,36 
For patients who have a short life expectancy and 
a large number of remaining access ites, revisions are 
less appealing, because only 16% to 23% of revisions 
remain patent 1 year later without another interven- 
tion. I f  revision of the failed PTFE is not believed to 
be a good option, the clinician usually has to choose 
between anew PTFE or aPDC, and consideration is 
given to risk factors that could contribute to another 
failure. In this study we found no effect of age, 
gender, smoking, diabetes, or prior PDC on hemo- 
dialysis access patency. However, a history of an 
unsalvageable PTFE shunt increased the risk of fail- 
ure for a new shunt, and this risk increased ramati- 
cally with the number ofptior shunts. Therefore, ifa 
PTFE shunt becomes unsalvageable, consideration 
should be given to testing the patient for a hyperco- 
agulable state and changing to peritoneal dialysis. 
When multiple failures occur, increasing the patient's 
priority for renal transplantation may be appropriate. 
In this study, we did not find diabetes to be a signif- 
icant risk factor for hemodialysis access failure, but 
this finding has been debated. 2,37,38 Because diabetes 
does appear to be a risk factor for PDCs, patients 
with diabetes are probably best treated with revision 
or replacement of hemoaccess, giving consideration 
to use of PDC only if the patient has had multiple 
hemodialysis graft failures. 
CONCLUSION 
Choosing a primary dialysis access is a complex 
process in which patient factors are the key consider- 
ation. Our results support he use ofAVFs, PTFEs, 
or PDCs for initial access, and many patients will 
have an obvious choice after considering anatomy, 
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risk factors, social issues, and strong patient prefer- 
ences. For the unusual patient who has no social or 
anatomic barriers to any form of access, PDCs or 
AVFs are an excellent choice in patients who do not 
have diabetes. PTFE is often the choice when access 
is urgent, because most patients will not  wish to have 
a hemodialysis catheter for the time period required 
for AVFs or PDCs to mature. PDCs are not  out of 
the question for patients with diabetes who are poor 
hemodialysis candidates, but patients with diabetes 
on peritoneal dialysis need to be reliable, and careful 
surveillance is needed to minimize problems with 
peritonitis and inadequate dialysis. As a result of  poor 
patency and inadequate dialysis flow rates, surgically- 
implanted ual- lumen hemodialysis catheters should 
be avoided whenever possible. With regard to op- 
tions after failure of a primary access, revisions can 
provide additional patency for PTFEs, AVFs, and 
PDCs with little risk in appropriately selected cases. 
Once a prosthetic shunt becomes unsalvageable, 
however, failure of the next shunt is more likely. 
Alternate therapy may become necessary, especially 
in patients who have multiple failed grafts. Lastly, 
comparing patency data for the various methods of 
dialysis access is useful, but reporting methods can 
dramatically alter the apparent results. Standard ef- 
initions of "failure" and "patency" are needed, and 
statistical reporting standards must be developed to 
make dialysis access outcomes from different centers 
interpretable. 
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